DMD – media

Sarepta Therapeutics and Brammer Bio Partnership to Develop Gene Therapy

Biopharma Sarepta Therapeutics and Brammer Bio enter into a long-term strategic partnership to design and develop new manufacturing facilities at CDMO’s plant in Massachusetts. The new partnership is for the development of the production of its microdystrophin, Duchenne Muscular Dystrophy (DMD) therapy and future gene therapies.
- Source: FiercePharma
- 601
- June 18, 2018
Company Insight DMD Gene therapy
Pfizer Doses First Patient Using Investigational Mini-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy (DMD). The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
- Source: finance.yahoo
- 626
- April 16, 2018
Clinical Trials DMD
Cambridge’s Exonics Therapeutics Scores $40M

Exonics Therapeutics closed on a $40 million Series A financing. It was led by The Column Group.
- Source: biospace
- 534
- December 7, 2017
DMD Market Views neuromuscular Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.